Jefferies analyst Andrew Tsai downgraded Avadel Pharmaceuticals (AVDL) to Hold from Buy with a price target of $20, down from $22, after Alkermes (ALKS) announced plans to acquire the company and its sleep franchise for up to $2.1B, including $1.9B upfront.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AVDL:
- Avadel Pharmaceuticals Acquired by Alkermes for $2.1 Billion
- Avadel Pharmaceuticals downgraded to Hold from Buy at Needham
- Morning Movers: GE Vernova climbs after third quarter earnings
- Wells Fargo says Avadel settlemnet adds $5 to Jazz Pharmaceuticals DCF
- Alkermes to acquire Avadel Pharmaceuticals for up to $20.00 per share in cash